← Eichor
Condition: Cutaneous Melanoma Stage Ii Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cutaneous Melanoma Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06999980A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Phase 2 · 1 location(s) · A.J.M. van den Eertwegh · NCT04126876A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · University of Louisville · NCT01638676Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Phase 2 · 2 location(s) · University of California, San Francisco · NCT04598009Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Phase 3 · 26 location(s) · Uppsala University · NCT06488482Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous M
NA · 1 location(s) · University Medical Center Groningen · NCT07206017A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
NA · 20 location(s) · Uppsala University · NCT03116412Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Phase 1/Phase 2 · 6 location(s) · The Netherlands Cancer Institute · NCT06240143Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Phase 2 · 9 location(s) · Melanoma Institute Australia · NCT03340129Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Phase 2 · 4 location(s) · Fudan University · NCT06965231Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07215988Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT05527795NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Phase N/A · 1 location(s) · AC Camargo Cancer Center · NCT07680699Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Phase 2 · 1 location(s) · Di Wu · NCT04331093Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to
Phase 1/Phase 2 · 1 location(s) · Kari Kendra · NCT05588453Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
Phase N/A · 27 location(s) · Assistance Publique - Hôpitaux de Paris · NCT02828202Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NA · 192 location(s) · Melanoma and Skin Cancer Trials Limited · NCT03860883IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04562129Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Phase 1 · 1 location(s) · Carlo Contreras · NCT04697576Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
Phase 2 · 1 location(s) · Vastra Gotaland Region · NCT07349303Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
NA · 4 location(s) · Erasmus Medical Center · NCT06643286Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05026983Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Phase N/A · 745 location(s) · Alliance for Clinical Trials in Oncology · NCT05334069
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.